Advanced Accelerator Applications
Advanced Accelerator Applications, a Novartis company, is an innovative radiopharmaceutical company developing, producing and commercializing molecular nuclear medicine theragnostics. AAA’s theragnostic platform is based on radiolabeling a targeting molecule with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy. AAA’s first theragnostic pairing for neuroendocrine tumors includes diagnostic drugs NETSPOT® and SomaKit TOC®; and therapeutic Lutathera®. Additional theragnostics in development target gastrointestinal stromal tumors (GIST), and prostate and breast cancer.